ArticleProceedings of the National Academy of Sciences of the United States of America2021
Homogeneous antibody and CAR-T cells with improved effector functions targeting SSEA-4 glycan on pancreatic cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Using Synthetic Glycans to Investigate Anti-Glycan Antibodies and Explore Their Medical Potential.Angewandte Chemie (International ed. in English) · 2026Review
- Review
- Improving the efficacy of anti-SSEA4 antibody in pancreatic cancer immunotherapy with glyco-optimization and immune checkpoint blockade.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Chemical and Enzymatic Synthesis of DisialylGb5 and Other Sialosides for Glycan Array Assembly and Evaluation of Siglec-Mediated Immune Checkpoint Inhibition.Molecules (Basel, Switzerland) · 2025Article
- A lipid metabolism related gene signature predicts postoperative recurrence in pancreatic cancer through multicenter cohort validation.Scientific reports · 2025Article
- Expression of Human β3GalT5-1 in Insect Cells as Active Glycoforms for the Efficient Synthesis of Cancer-Associated Globo-Series Glycans.Journal of the American Chemical Society · 2025Article
- Structure-Based Mechanism and Specificity of Human Galactosyltransferase β3GalT5.Journal of the American Chemical Society · 2025Article
- Profiling the regulatory landscape of sialylation through miRNA targeting of CMP- sialic acid synthetase.The Journal of biological chemistry · 2025Article
- Screening the human miRNA interactome reveals coordinated up-regulation in melanoma, adding bidirectional regulation to miRNA networks.Science advances · 2025Article
- Current Landscape of Therapeutic Cancer Vaccines.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Making Universal Vaccines and Antibodies Through Glycoengineering.Methods in molecular biology (Clifton, N.J.) · 2025Review
- CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies.Frontiers in endocrinology · 2025Review
- MUC1 expression is associated with ST3GAL2 and negatively correlated with the androgen receptor in castration-resistant prostate cancer.Glycoconjugate journal · 2024Article
- Ganglioside SSEA-4 in Ewing sarcoma marks a tumor cell population with aggressive features and is a potential cell-surface immune target.Scientific reports · 2024Article
- Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept.Journal of experimental & clinical cancer research : CR · 2024Review
- Probing the Internalization and Efficacy of Antibody-Drug Conjugate via Site-Specific Fc-Glycan Labelling of a Homogeneous Antibody Targeting SSEA-4 Bearing Tumors.Israel journal of chemistry · 2023Article
- Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value.Molecular therapy. Methods & clinical development · 2023Article
- Anti-glycan monoclonal antibodies: Basic research and clinical applications.Current opinion in chemical biology · 2023Review
- Study on antibody Fc-glycosylation for optimal effector functions.Chemical communications (Cambridge, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Pancreatic cancer is usually asymptomatic in the early stages; the 5-y survival rate is around 9%; and there is a lack of effective treatment. Here we show that SSEA-4 is more expressed in all pancreatic cancer cell lines examined but not detectable in normal pancreatic cells; and high expression of SSEA-4 or the key enzymes
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.